Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00745134 · ClinicalTrials.gov registry record · Phase 2
Radiation Therapy and Capecitabine With or Without Curcumin Before Surgery in Treating Patients With Rectal Cancer
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT00745134: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00745134 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00745134, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
This randomized phase II trial studies how well radiation therapy and capecitabine with or without curcumin before surgery works in treating patients with rectal cancer. Drugs such as curcumin may make tumor cells more sensitive to radiation therapy. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy with radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. It is not yet known whether chemotherapy and radiation therapy is more effective with or without curcumin when given before surgery in patients with rectal cancer.
Interventions
- DRUG Capecitabine
- OTHER Placebo
- OTHER Laboratory Biomarker Analysis
- DIETARY_SUPPLEMENT Curcumin
- OTHER Pharmacological Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2008-08-11 |
| Est. Completion | 2022-11-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00745134
The ClinicalTrials.gov registry entry for NCT00745134 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Capecitabine is the first listed.
NCT00745134 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00745134 about?
NCT00745134 is a clinical study titled "Radiation Therapy and Capecitabine With or Without Curcumin Before Surgery in Treating Patients With Rectal Cancer". This randomized phase II trial studies how well radiation therapy and capecitabine with or without curcumin before surgery works in treating patients with rectal cancer. Drugs such as curcumin may make tumor cells more sensitive to radiation therapy. Drugs used in chemotherapy, such as capecitabine,...
What is the current status of trial NCT00745134?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2008-08-11. Estimated completion is 2022-11-11.
What interventions are being tested in trial NCT00745134?
The interventions under investigation include: Capecitabine (DRUG), Placebo (OTHER), Laboratory Biomarker Analysis (OTHER), Curcumin (DIETARY_SUPPLEMENT), Pharmacological Study (OTHER).
Who is sponsoring clinical trial NCT00745134?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.